Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its segments include the Biopharm Division and Neurostimulation Division. Its pipeline includes NPM-139, NPM-133, NPM-115 and OKV-119. NPM-139 is a six-month, semaglutide implant under development for the treatment of chronic weight management. NPM-115 is an exenatide-based implant candidate also under development for the treatment of chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed for once or twice-yearly administration of medication.
Back to dashboard
Company Information
About this company
Key people
Gregg G. Williams
Non-Executive Independent Chairman of the Board
Aaron Mendelsohn
Independent Director
Adam Mendelsohn
Chief Executive Officer, Director
Anthony Baldor
Chief Financial Officer
Truc Le
Chief Operating Officer
Lisa Porter
Chief Medical Officer
Donald Dwyer
Corporate Secretary, Chief Business Officer
Dean Baker
Independent Director
Daniel Mark Bradbury
Independent Director
Alexandra Larson
Independent Director
Click to see more
Key facts
- Shares in issue90.20m
- EPICVANI
- ISINUS92854B1098
- LocationUnited States
- SectorHealthcare
- IndustryMedical Equipment & Supplies
- Market cap$114.56m
- Employees42
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.